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Abstract
Background: The aim of this study was to compare the efficacy, safety, costs, and cost-effectiveness of biphasic insulin
aspart 30 (BIAsp 30) with NPH plus regular human insulin (NPH/Reg) in patients with type 2 diabetes mellitus (T2DM).
Methods: It was a Single-center, parallel-group, randomized, clinical trial (Trial Registration: NCT01889095). One
hundred and seventy four T2DM patients with poorly controlled diabetes (HbA1c≥ 8 % (63.9 mmol/mol)) were
randomly assigned to trial arms (BIAsp 30 and NPH/Reg) and were followed up for 48 weeks. BIAsp 30 was started at
an initial dose of 0.2–0.6 IU/Kg in two divided doses and was titrated according to the glycemic status of the patient.
Similarly, NPH/Reg insulin was initiated at a dose of 0.2–0.6 IU/Kg with a 2:1 ratio and was subsequently titrated. Level
of glycemic control, hypoglycemic events, direct and indirect costs, quality adjusted life year (QALY) and incremental
cost-effectiveness ratio have been assessed.
Results: HbA1c, Fasting plasma glucose (FPG), and two-hour post-prandial glucose (PPG) were improved in both
groups during the study (P < 0.05 for all analyses). Lower frequencies of minor, major, and nocturnal hypoglycemic
episodes were observed with BIAsp 30 (P < 0.05). Additionally, BIAsp 30 was associated with less weight gain and also
higher QALYs (P < 0.05). Total medical and non-medical costs were significantly lower with BIAsp 30 as compared with
NPH/Reg (930.55 ± 81.43 USD vs. 1101.24 ± 165.49 USD, P = 0.004). Moreover, BIAsp 30 showed lower ICER as a
dominant alternative.
Conclusions: Despite being more expensive, BIAsp 30 offers the same glycemic control as to NPH/Reg
dose-dependently and also appears to cause fewer hypoglycemic events and to be more cost-effective in Iranian
patients with type 2 diabetes.
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Background
Type 2 diabetes mellitus (T2DM) is the most common
metabolic disease in the world with highly cost-
demanding complications [1, 2]. Glycemic control is the
mainstay of treatment in patients with diabetes mellitus
and can be achieved via medical nutritional therapy [3, 4],
physical activity, oral medications, and insulin therapy [5].
Tight glycemic control, with glucose concentrations as
close as possible to the non-diabetic range, has been dem-
onstrated to reduce diabetes-related complications includ-
ing retinopathy, nephropathy, cardiovascular diseases and
overall mortality [6, 7]. However, incident hypoglycemia
poses a significant barrier to achievement of the targeted
level of glycemic control; even a single episode could re-
sult in catastrophic consequences [8]. American Diabetes
Association (ADA) recommends that, irrespective of the
treatment strategy employed, precautions should be im-
plemented in order to avoid hypoglycemia [5]. Given the
lifelong course of diabetes, treatment strategies should
take a number of aspects into consideration, among which
medication efficacy, patient satisfaction, and costs of
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therapy are of particular importance [9]. It is recom-
mended that if lifestyle modification and full tolerated
doses of one or two oral glucose lowering drugs (OGLDs)
fail to achieve or sustain glycemic goals, then insulin ther-
apy should be initiated [10]. Over the past decade, insulin
analogs have gained recognition since they offer numerous
advantages over the traditional preparations with regard
to blood glucose variability, number of injections needed,
patient satisfaction, and life expectancy [11–14].
Despite these advantages, the cost of insulin analogs is
a major problem. For instance, Palmer and colleagues
have shown that switching from traditional preparations
to biphasic insulin Aspart 30 (BIAsp 30) would result in
an additional $ 9000 in terms of life-time direct medical
costs [15]. A number of previous studies have delineated
the efficacy, safety, and cost-effectiveness of BIAsp 30 in
patients with diabetes [14–17]; yet the cost-effectiveness
of such therapy has not been explored in Iran. The aim
of the present piggyback study was to investigate the
cost-effectiveness of BIAsp 30 using the data from a
clinical trial Iranian patients with T2DM.
Methods
Study design and participants
The analysis of the present study is based on the data
collected in the single-center, randomized, parallel-
group, clinical trial conducted between July 2011 and
October 2012 in Diabetes clinic of the Vali-Asr hospital
(a teaching hospital affiliated with Tehran University of
Medical Sciences, Tehran, Iran). Two hundred and four
T2DM patients currently taking OGLDs were initially
assessed. Patients were included if had HbA1c >8.0 %
despite adequate therapy with lifestyle modification and
one or two classes of OGLDs. Exclusion criteria were as
follows: (1) recent surgery or clinically significant infec-
tion, (2) treatment with glucocorticoids, (3) incidence of
severe hypoglycemic episode requiring hospital admission
or visit by a healthcare professional; (4) previous use of any
type of insulin; (5) presence of diabetes retinopathy signifi-
cant enough to require treatment in the past 6 months; (6)
estimated glomerular filtration rate < 50 mL/min/1.73 m2;
(7) pregnancy, breast-feeding, planning to become pregnant
in the next year, or use of inadequate contraceptive measur-
ing in women of child-bearing age; and (8) current partici-
pation in other clinical studies. A total of 174 patients met
the inclusion criteria and were assigned to either of the trial
arms with the aid of randomization software.
Ethics, consent and permissions
The trial was approved by the Institutional Review Board
at the Tehran University of Medical Sciences (project
number: 90-03-33-15600) and it is also registered with
ClinicalTrial.gov (Reg. No.: NCT01889095). After fully
disclosing the purpose of the study, written informed
consent was obtained from each patient. All procedures
involving human subjects were conducted in accordance
with the guidelines laid down the recent revision of
Helsinki declaration.
Interventions
The insulin therapies were prescribed by a single phys-
ician in the clinic (A.E.). The starting dose of BIAsp 30
(NovoMix® 30-pen, NovoNordisk) was 0.2–0.6 unit/kg
per day injected in two divided doses (pre-breakfast and
pre-dinner). The other arm of the trial received NPH/
Reg insulin (Exir pharmaceuticals, Lorestan, Iran) in a
Ratio of 2:1 with initiation dose of 0.2–0.6 unit/kg in
injected in two divided doses. Two-thirds of the dose
was given before breakfast and the remainder before
dinner. Initiation of NPH/Reg therapy was provided in
an in-patient setting for careful monitoring of blood glu-
cose. Continuation and/or dose modification of OGLDs
at the time of starting the insulin regimen and through-
out the study was entirely at the discretion of the treat-
ing physician guided by glycemic control achieved.
Patients were asked to record their 7-point blood glu-
cose values in three consecutive days before each visit.
Seven-point self-monitoring blood glucose includes
three pre-meals, three post-meals, and one bedtime
blood glucose readings, each day. Patients received in-
struction from a nurse regarding usage of the gluc-
ometer for capillary glucose monitoring. Insulin doses
were adjusted by a titration regimen according to the
self-monitored blood glucose sheets. For both groups,
treatment goals were set as follows: fasting blood glucose
of 80–120 mg/dl, postprandial glucose <160 mg/dl,
HbA1c <7 % and the before dinner blood glucose target
for the NPH/Reg insulin group was 100 mg/dl. Stepwise
increases in dosage of insulin in both arms was done de-
pending on the pre-meal blood glucose values to achieve
targets for plasma glucose (PG) as follows: +2 IU/day
where 126 mg/dl < PG ≤ 140 mg/dl, +4 IU/day where
140 mg/dl < PG ≤ 160 mg/dl, +6 IU/day where 160 mg/dl
< PG ≤ 180 mg/dl, +8 IU/day where 180 mg/dl < PG ≤
200 mg/dl and +10 IU/day where PG > 200 mg/dl [18, 19],
unless hypoglycemia occurred. Hypoglycemia was defined
as blood glucose <70 mg/dl [20]. Severe hypoglycemia was
defined as an event with symptoms consistent with
hypoglycemia where the individual required the assistance
of another person and was not treated with oral carbohy-
drate due to confusion or being unconsciousness and was
associated with a blood glucose level <40 mg/dl with
recovery with intravenous glucose, or glucagon adminis-
tration. Nocturnal hypoglycemia was defined as
hypoglycemia occurred at night and is commonly known
as hypoglycemia while asleep. Data were collected at each
visit during the study period (see below).
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Assessments
Patients in the both arms of the trial were visited at base-
line, and then with 12-weeks interval thereafter. There-
fore, five visits at weeks 0, 12, 24, 36, and 48 were
conducted. The initial visit included evaluation for meet-
ing the inclusion criteria followed by acquiring a detailed
medical history along with performance of a thorough
physical examination. Specific checklists for determination
of medical, non-medical and productivity costs were also
completed at each visit during study period (between July
2011 and October 2012). QALY was assessed using the
self-administered standard EQ-5D-3 L questionnaire [21].
Laboratory measurements
Laboratory evaluations were performed at baseline and
every 12 weeks thereafter. After an overnight fasting of at
least 12 h, venous blood samples were drawn and were
sent to hospital laboratory for analysis. Fasting plasma glu-
cose (FPG) concentrations were determined using the glu-
cose oxidase method. Serum concentrations of two-hour
post-prandial glucose (PPG) were assessed using a glucose
analyzer (YSI 2700 Select, YSI, Inc., Yellow Springs, OH).
Percentage of glycated hemoglobin A1c (HbA1c) was
measured using the high performance liquid chromatog-
raphy (HPLC) method [22]. Serum concentrations of total
cholesterol, high-density lipoprotein cholesterol (HDL),
low density lipoprotein cholesterol (LDL), and triglycer-
ides were determined using enzymatic methods with avail-
able commercial kits (Pars Azmun, Karaj, Iran) in a
Hitachi 704 automatic analyzer (Tokyo, Japan) [23].
Analysis of costs
Direct medical/non-medical costs and indirect costs as
described and published by Farshchi et al. [2], were calcu-
lated using a checklist. Costs from the societal perspective
were converted from Iranian Rials (IRR) into USA dollar
(USD) at an official exchange rate of 12,260 IRR/1USD
2012 to have an international comparison [24].
Utility calculation
Utility scores were calculated by two well-known mea-
surements; European Quality of Life-5 Dimensions,-3
Levels (EQ-5D-3 L) from 0 to 1 and Visual Analogue
Scale (VAS) between 0 and 100. These are two standard-
ized measures of health status and quality adjusted life
year (QALY), developed by the EuroQol group in order
to provide a simple, generic measure of health for
clinical and economic appraisal [25].
Cost-effectiveness analysis
QALYs and number of reduction in hypoglycemic events
were considered as outcomes and the incremental cost
effectiveness ratio (ICER) per patient was calculated ac-
cording to the below formula: ICER = ΔCost/ ΔOutcome
[26, 27]. The comparison of ICERs per each outcome
was held afterwards. Based on recommendation of the
World Health Organization (WHO) [28], the ICER were
compared with the gross domestic product (GDP) per
capita. The GDP per capita of Iran was recorded as 6578
USD in 2012 [29].
Statistical analysis
Continuous variables are presented as mean ± standard de-
viation (SD) and categorical ones as proportions. Between
groups comparisons were conducted using Student’s t-test
for continuous variables, and Pearson’s Chi square for cat-
egorical ones. Difference in the outcome variables of inter-
est between trial arms was investigated using the analysis of
variance (ANOVA) and paired t-test methods. All analyses
were conducted using Software Package for Social Sciences
(version 14 for Windows; SPSS Inc., Chicago, IL). P values
< 0.05 were considered statistically significant.
Results
Two hundred and four subjects were initially assessed;
174 met the inclusion criteria and were therefore allocated
to BIAsp (n = 90) or NPH/Reg (n = 84) arms of the trial.
Eight subjects in the BIAsp 30, and two in the NPH/Reg
arm did not return for the follow up visits and were lost
to follow up. Overall, 164 patients or 94.3 % completed
the trial. The CONSORT flow diagram of the trial is
depicted in Fig. 1. Baseline characteristics of trial partici-
pants are presented in Table 1. Patients’ characteristics
were comparable between the two arms of the trial. Base-
line HbA1c concentrations were comparable (9.55 ± 1.03
vs. 9.97 ± 1.52 %, P = 0.576) and disease duration was
13.60 ± 3.12 years vs. 15.62 ± 4.86 years in BIAsp 30 and
insulin NPH/Reg insulin group (P = 0.194), respectively.
Insulin therapy
No serious adverse drug reactions were reported. In
BIAsp 30, insulin dose increased over the trial course
from a daily mean starting dose of 0.32 ± 0.06 to 0.76 ±
0.14 IU/kg. The pre-breakfast dose of BIAsp 30 in-
creased from the mean starting dose of 0.16 ± 0.03 to
0.38 ± 0.07 IU/kg, whereas the pre-dinner dose increased
from the mean starting dose of 0.16 ± 0.04 to 0.37 ±
0.05 IU/kg at the end of the trial. Similarly, NPH/Reg in-
sulin dose increased from a daily mean starting dose of
0.34 ± 0.05 to 0.80 ± 0.07 IU/kg. The pre-breakfast dose
of NPH/Reg insulin increased from the mean starting
dose of 0.18 ± 0.04 to 0.41 ± 0.06 IU/kg, while pre-dinner
dose increased from the mean starting dose of 0.18 ±
0.03 to 0.40 ± 0.07 IU/kg by the end of the trial.
Glycemic control
Table 2 shows metabolic control for each trial arm at
baseline and after 48 weeks of insulin therapy. Overall,
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the percentage of patients achieving HbA1c level of
<7.0 % was 49 % at week 48 (65 % for BIAsp 30 and
33 % for NPH/Reg insulin); considerable decrease in
HbA1c values were seen with both NPH/Reg insulin and
BIAsp 30. Although BIAsp 30 decreased FPG and PPG
concentrations to a larger extent, the difference did
not reach statistical significance (132.00 ± 13.2 vs.
144.33 ± 8.16, P = 0.122). On the other hand HbA1c
levels decreased 2.40 ± 1.28 % in BIAsp 30 and 2.34 ±
1.53 % in NPH/Reg insulin groups while there was no
statistically significant difference between groups (P =
0.233).
Hypoglycemic events were evaluated as minor, major
and nocturnal hypoglycemic episodes and are described
in Table 3. Minor, major, and nocturnal events were
more frequent among patients in the NPH/Reg arm (P <
0.05 in all cases). Consequently, the frequency of total
events were higher in NPH/Reg arm (P = 0.002).
Fig. 1 CONSORT flow diagram
Table 1 Baseline characteristics of the trial participants
Trial arms
BIAsp 30 (n = 82) NPH/Reg (n = 82) P value
Age (years) 58.50 ± 14.04 57.24 ± 10.88 0.072
Sex (male/female) 33/49 29/53 0.343
Diabetes Duration (years) 13.60 ± 3.12 15.62 ± 4.86 0.194
HbA1c (%) 9.55 ± 1.03 9.97 ± 1.52 0.576
TG (mg/dl) 183.19 ± 11.33 191.22 ± 55.11 0.153
Total Chol (mg/dl) 184.41 ± 21.31 176.33 ± 22.30 0.254
LDL (mg/dl) 103.72 ± 19.70 110.39 ± 14.56 0.348
HDL (mg/dl) 45.34 ± 11.05 48.55 ± 15.12 0.176
BMI (kg/m2) 29.37 ± 6.78 31.78 ± 7.52 0.211
Prior OGLD treatment (n, %) Metformin 25 (30.48) 27 (32.92) 0.972
Sulfonylurea 9 (10.97) 9 (10.97)
Metformin + Sulfonylurea 40 (48.78) 39 (47.56)
Thiazolidinedione 4 (4.87) 5 (6.09)
Abbreviations: BIAsp biphasic insulin aspart 30, NPH/Reg NPH plus regular human insulin, HbA1c hemoglobin A1c, TG triglyceride, Chol cholesterol, LDL low density
lipoprotein, HDL high density lipoprotein, BMI body mass index, OGLD oral glucose lowering drugs
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BIAsp 30 was also associated with less weight gain
(+0.22 ± 1.55 vs. +2.10 ± 2.69, P = 0.045).
Costs
Direct costs
Mean direct costs were 595.15 ± 30.15USD for BIAsp 30
and 726.34 ± 60.34 USD for NPH/Reg arm (Table 4).
Total direct medical costs in NPH/Reg insulin arm were
higher than BIAsp 30 group (P = 0.017). Medications
and inpatients cost were significantly higher in NPH/Reg
insulin group (P < 0.05), it was due to more admissions
and longer stay in hospital, while there were not statisti-
cally significant differences in laboratory and clinical
visits between groups (P > 0.05). Although direct non-
medical costs in NPH/Reg insulin group were higher
than BIAsp 30 group (Table 4), this difference did not
reach statistical significance (P = 0.332).
Indirect costs
Costs of lost productivity were higher in NPH/Reg insulin
group (Table 4). Mean indirect costs for BIAsp 30 was
340.4 ± 42.21 USD while this figure was 375.45 ± 70.33
USD for NPH/Reg arm with no significant difference (P =
0.271). Total cost was estimated to be 930.55 ± 81.43 USD
for BIAsp 30 and 1101.24 ± 165.49 USD for NPH/Reg arm.
Utility
EQ-5D-3 L and VAS scores improved during the trial in
patients in both groups. But treatment with BIAsp 30
significantly lead to higher QALYs (P = 0.011). There was
no significant difference in QALY scores during the trial
in NPH/Reg group. Mean difference of QALY scores for
EQ-5D-3 L were 0.12 ± 0.05 and 0.04 ± 0.02 for BIAsp
30 and NPH/Reg insulin groups after 48 weeks, while
there were 0.14 ± 0.06 and 0.05 ± 0.04 for VAS respect-
ively (Table 2).
Cost effectiveness analysis
The cut-off for ICER was approximately 20000 $ per QALY.
Regarding major clinical outcomes (i.e. hypoglycemia events
and QALY) BIAsp 30 showed lower ICER as a dominant al-
ternative (Table 5).
Discussion
In the present randomized clinical trial, efficacy, safety,
cost, and cost-effectiveness of BIAsp 30 and NPH/Reg in-
sulin regimens were compared. After 48 weeks, patients in
both trial arms experienced a significant improvement in
glycemic control as evidenced by substantial decreases in
serum concentrations of FPG, PPG, and HbA1c. By the
end of the trial, 65 % of patients in the BIAsp 30 arm, and
33 % of the patients in the NPH/Reg arm achieved gly-
cemic goals delineated by the ADA [5] (P = 0.032). Al-
though observed rate for BIAsp 30 is higher, it is still
Table 2 Metabolic control and QALY for the study population at baseline and after 48 weeks of insulin analog therapy
Trial arms
BIAsp 30 (n = 82) NPH/Reg Insulin (n = 82)
Baseline 48 weeks P value Baseline 48 weeks P value
HbA1c (%) 9.55 ± 1.03 7.15 ± 0.24 0.021 9.97 ± 1.52 7.62 ± 0.21 0.011
FPG (mg/dl) 208.10 ± 4.51 144.33 ± 8.16 0.029 185.76 ± 12.1 132.00 ± 13.2 0.027
PPG (mg/dl) 276.84 ± 9.2 211.51 ± 10.3 0.032 239.25 ± 12.55 180.88 ± 12.90 0.019
TG (mg/dl) 183.19 ± 11.33 173.44 ± 12.50 0.247 191.22 ± 55.11 170.42 ± 40.18 0.631
Total Chol (mg/dl) 184.41 ± 21.31 169.41 ± 15.13 0.471 176.33 ± 22.30 161.28 ± 18.34 0.259
LDL (mg/dl) 103.72 ± 19.70 101.89 ± 16.42 0.554 110.39 ± 14.56 98.44 ± 19.45 0.131
HDL (mg/dl) 45.34 ± 11.05 49.45 ± 18.65 0.398 48.55 ± 15.12 47.47 ± 19.35 0.228
BMI (kg/m2) 29.37 ± 6.78 29.59 ± 3.62 0.421 31.78 ± 7.52 33.88 ± 2.89 0.166
QALY
EQ-5D-3 L 0.59 ± 0.03 0.73 ± 0.04 0.031 0.64 ± 0.11 0.66 ± 0.06 0.082
VAS 0.61 ± 0.05 0.75 ± 0.06 0.026 0.69 ± 0.04 0.71 ± 0.08 0.074
Abbreviations: BIAsp biphasic insulin aspart 30, NPH/Reg NPH plus regular human insulin, HbA1c hemoglobin A1c, TG triglyceride, Chol cholesterol, LDL low density
lipoprotein, HDL high density lipoprotein, BMI body mass index, QALY quality adjusted life year, EQ-5D-3 L European quality of life-5 dimensions -3 levels, VAS and
visual analogue scale
Table 3 Frequency of hypoglycemic events in trial arms reported
as per person-year
Trial arms
Type of event BIAsp 30 (n = 82) NPH/Reg (n = 82) P value
Minor 7.28 ± 3.51 21.60 ± 7.18 0.012
Major 2.76 ± 1.12 7.68 ± 4.32 0.031
Nocturnal 10.04 ± 3.61 21.48 ± 6.72 0.026
Total 20.08 ± 5.60 50.76 ± 11.50 0.002
Abbreviations: BIAsp biphasic insulin aspart 30, NPH/Reg NPH plus regular
human insulin
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significantly lower than the rated reported in clinical trials
of shorter or equal duration. Raskin et al., in a trial of
insulin-naïve T2DM patients treated with 5–6 units BIAsp
30 twice daily were able to achieve HbA1c < 7.0 % in 66 %
of patients by week 28 [30]. In the 1–2–3 study by Garber
et al., a step-by-step incremental regimen of BIAsp was
able to attain ADA targets in 70 % of T2DM patients by
32 weeks of injections twice daily. This rate increased to
77 % by an additional 16 weeks of injections thrice daily
[31]. In a double-blind parallel-group randomized trial of
403 T2DM patients, efficacy and safety of BIAsp 30 with
NPH was compared. After 16-weeks of insulin therapy,
BIAsp 30 proved to be superior in reducing postprandial
glucose and was at least as effective in HbA1c reduction
Safety and efficacy profiles of the two regimens were also
comparable [32]. Similar results have been replicated in
type 1 and type 2 diabetes populations [33]. Along the
same lines, McSorely et al. demonstrated that compared
with biphasic human insulin 30, BIAsp 30 twice daily pro-
vides greater mean insulin concentrations both after
breakfast and after dinner; induces earlier postprandial
peaks; and finally produces lower glucose excursions four
hours after the injection [34].
The most serious adverse effect of insulin therapy is
hypoglycemia, but the frequency and severity of this ef-
fect is less in type 2 diabetes than in type 1 diabetes
[35]. In the United Kingdom Prospective Diabetes Study
(UKPDS) major hypoglycemia occurred in 2.3 % of pa-
tients per year who were treated with insulin compared
with rates of 0.6 % in those on sulfonylurea therapy [36].
The risk of hypoglycemia increases significantly when
the HbA1c level is below 7.4 % [37]. Despite comparable
glycemic control between BIAsp 30 and NP/Reg,
hypoglycemia episodes (including minor, major, and noc-
turnal events) were significantly more frequent among
NPH/Reg patients. This might be due to slow absorption
of regular human insulin from the subcutaneous tissue
which leads to a delayed peak two to three hours after
injection [38]. Consequently, post-meal hyperglycemia
followed by delayed postprandial hypoglycemia ensues.
Additionally, absorption rates for the conventional basal
NPH insulin vary and its duration of action is shorter
than 24 h. These pharmacodynamics limitations may re-
sult in high fasting blood glucose and nocturnal
hypoglycemia [39, 40]. Contrarily, biphasic analogs such
as BIAsp 30 have a more rapid onset of action that re-
sults in more effective reduction of postprandial glucose,
diminishing the chance of occurrence of hypoglycemia
[41]. The efficacy and safety of BIAsp 30 have been
widely documented in randomized clinical trials and ob-
servational studies [17, 31, 42, 43]. The results achieved
in this study showed that initiating insulin therapy with
BIAsp 30 resulted in lower rates of hypoglycemia, and
higher QALYs compared to NPH/Reg insulin.
Weight gain is a common side effect with insulin ther-
apy and could hamper the positive outcomes gained by
its anti-hyperglycemic effects [44]. Since the majority of
T2DM patients are already overweight/obese, both
Table 4 Direct and indirect costs of insulin therapy in trial arms reported in USD
Trial arms
Type of cost Subcategory BIAsp 30 (n = 82) NPH/Reg Insulin (n = 82) P value
Direct costs Laboratory 55.3 ± 12.9 51.1 ± 11.1 0.732
Medications 225.8 ± 41.7 60.5 ± 22.6 0.024
Clinical visits 55.9 ± 13.8 56.2 ± 9.3 0.815
Inpatient 235.4 ± 51.8 535.9 ± 37.8 0.009
Non-medical 17.7 ± 4.9 22.0 ± 4.2 0.332
Indirect costs Productivity loss 340.4 ± 42.2 375.4 ± 70.3 0.271
Total 930.5 ± 81.4 1101.3 ± 165.5 0.004
Abbreviations: USD U.S. dollars, BIAsp biphasic insulin aspart 30, NPH/Reg NPH plus regular human insulin
Table 5 Cost-effectiveness analysis for hypoglycemic events and utility outcomes
Trial arms
BIAsp 30 (n = 82) NPH/Reg (n = 82)
Hypoglycemia event per person-year 20.08 ± 5.60 50.76 ± 11.50
Mean difference of QALY (EQ-5D-3 L) 0.12 ± 0.05 0.04 ± 0.02
Mean difference of QALY (VAS) 0.14 ± 0.06 0.05 ± 0.04
Costs (USD) 930.55 ± 81.43 1101.24 ± 165.49
ICER Dominant —
Abbreviations: BIAsp biphasic insulin aspart 30, NPH/Reg NPH plus regular human insulin, QALY quality adjusted life year, EQ-5D-3 L European quality of life-5 dimensions
-3 levels, VAS and visual analogue scale, USD U.S. dollars, ICER incremental cost-effectiveness ratio
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patients and the physician are concerned that insuliniza-
tion would result in further gains in body weight. There-
fore, this issue is an important determining factor in
choosing the type of insulin. In the UKPDS patients tak-
ing insulin gained 4 kg more than those treated with diet
therapy over 10 years [36]. It has been suggested weight
gain can be modified by increasing exercise, restricting
calories, and administering metformin concurrently [33,
37]. In the present study, less weight gain was achieved
with BIAsp 30 compared with NPH/Reg although, in
contrast to our results, in a review of literature weight
gain during treatment was not different between BIAsp
30 and biphasic human insulin 30 [45]. However, the
benefits of insulin administration outweigh the health
risks of increased weight.
Our findings corroborate and complement the IM-
PROVE™ study which showed addition of BIAsp 30 to
treatment protocol of T2DM patients not only substan-
tially improves glycemic control, but also is associated
with an enhanced quality of life [17]. Our analysis also
revealed that switching from OGLDs to insulin does not
increase treatment burden due to injectable insulin nei-
ther in patients treated with BIAsp 30 nor in the NPH/
Reg arm. In addition, the health status improved in both
groups during the study though the change was only sta-
tistically significant for the BIAsp 30 patients. Similarly,
insulin analogs have been shown to increase patients’
health-related quality of life (HRQoL) compared with
human insulin [46, 47]. Patients with improved HRQoL
are more likely to adhere to prescribed treatment regi-
mens and insulinization, thereby achieving better gly-
cemic control [48]. Consequently, this may lower the
expenses related to poor compliance or delayed adoption
of insulin therapy [49]. An observational study in the
United States has shown that adherence to insulin ther-
apy increases and incident hypoglycemia decreases when
patients are switched from the traditional vial and syr-
inge system to insulin analog pen devices [50]. In an-
other study, Brod et al. found that patients who were
treated with BIAsp 30 reported improved treatment satis-
faction after 26 weeks and that was large enough to be con-
sidered clinically meaningful to the patients [51]. It should
also be noted that occurrence of major hypoglycemic epi-
sodes and weight gain both have detrimental effects on pa-
tients’ HRQoL and enhanced QALYs of the patients
receiving BIAsp 30 could in part be accounted for by its su-
perior profile in this regard [52].
Cost analysis
Increases in health care costs have an important concern
for health care policy makers. Many studies have de-
scribed the economic impact of diabetes on health care
systems [53–56]. Considering the findings of two related
studies, T2DM and its complications impose a large
economic burden on the individual and health care sys-
tem in Iran [2, 53]. Taking the disease burden and the
growing pandemic of diabetes into account, we should
select the most cost effective strategies to control the in-
creasing costs. Although insulin analogs are more ex-
pensive to the payer than human insulin, insulin analogs
may be able to reduce more expensive long-term expen-
ditures such as the costs related to treatment of
hypoglycemia or chronic complications of DM [49]. The
results of this study demonstrated that treatment with
BIAsp 30 was associated with improvements in glucose
control and QALY in comparison with treatment with
NPH/Reg insulin in patients with T2DM. Treatment
with BIAsp 30 was also associated with reduction in
total costs rather than NPH/Reg insulin. WHO’s recom-
mendation about threshold of developing countries con-
siders ICER less than triplet of GDP as a cost-effective
intervention [28]. Accordingly, treatment of T2DM is cate-
gorized as “highly cost effective” if the ICER is less than
GDP per capita; “cost-effective” if the cost/QALY was be-
tween one to three times of GDP per capita, and “not cost-
effective” if it was more than three times of GDP per capita.
Our analysis showed that treating poorly controlled pa-
tients with BIAsp 30 is likely to be cost-saving and cost-
effective in Iran. In parallel to the results of our study, vari-
ous studies have shown better glycemic control and more
tolerability with insulin analogs compared with human in-
sulin in patients with T2DM [57–59]. Subsequently, cost-
effectiveness of BIAsp 30 could be attributed to lower inci-
dence of hypoglycemia in short-term and better prevention
of DM related complications in long-term [60, 61]. Along
the same lines, it has been demonstrated that total annual
cost-savings with insulin analogs is 1590 USD per patient,
of which 788 USD is hypoglycemia-related cost-savings and
600 USD is due to other DM-related cost-savings [50].
There was not any insulin allergy observed in our patients
because all insulins are made using genetic recombinant
techniques thus, insulin allergy is uncommon.
Conclusion
In conclusion, the present randomized, open-label clin-
ical trial revealed that biphasic analog BIAsp 30 is at
least as effective as NPH/Reg with respect to glycemic
control, and is associated with lower incidence of
hypoglycemia episodes and higher QALY. When these
gains are translated into cost-effectiveness analysis, it ap-
pears that BIAsp 30 is significantly more cost-effective
than the NPH/Reg regimen and could better prevent
long-term complications of T2DM when prescribed
alongside OGLDs.
Limitations
There were some limitations in this study. We did not cal-
culate cost of hypoglycemia separately, thus the impact of
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hypoglycemia on total cost was not measurable. In
addition, this study was conducted in Iranian population,
therefore, the results would be generalizable to other
population with caution.
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